Lisanti Capital Growth LLC Invests $5.57 Million in Heartflow, Inc. $HTFL

Lisanti Capital Growth LLC purchased a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 189,675 shares of the company’s stock, valued at approximately $5,565,000. Lisanti Capital Growth LLC owned about 0.22% of Heartflow as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. AlpInvest Partners B.V. acquired a new stake in Heartflow during the 2nd quarter worth approximately $1,071,000. BlackRock Inc. acquired a new position in shares of Heartflow in the second quarter valued at approximately $152,502,000. Deutsche Bank AG purchased a new stake in shares of Heartflow during the second quarter worth approximately $2,320,000. Bank of New York Mellon Corp acquired a new stake in shares of Heartflow during the second quarter worth $19,096,000. Finally, Walleye Capital LLC purchased a new position in Heartflow in the 2nd quarter valued at $8,760,000.

Heartflow Trading Up 0.7%

Shares of Heartflow stock opened at $45.53 on Thursday. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $47.23. The stock has a market cap of $3.96 billion and a PE ratio of -24.88. The company has a 50-day moving average of $30.00 and a two-hundred day moving average of $28.05.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, sell-side analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Morgan Stanley upped their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Piper Sandler reiterated an “overweight” rating and issued a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th. Finally, Wells Fargo & Company raised their target price on Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Heartflow has an average rating of “Moderate Buy” and a consensus price target of $43.43.

Insider Buying and Selling at Heartflow

In other Heartflow news, CEO John C.M. Farquhar sold 38,900 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the sale, the chief executive officer directly owned 457,935 shares in the company, valued at approximately $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $41.23, for a total value of $380,099.37. Following the completion of the sale, the insider directly owned 86,459 shares in the company, valued at $3,564,704.57. This trade represents a 9.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 131,365 shares of company stock valued at $4,257,216. 7.70% of the stock is currently owned by insiders.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.